Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
22.56
+0.03 (0.13%)
Feb 11, 2025, 4:00 PM EST - Market closed
Beta Bionics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -55.5 | -44.1 | -64.75 |
| Depreciation & Amortization | 2.3 | 2.09 | 2.09 |
| Other Amortization | - | - | 0.01 |
| Loss (Gain) From Sale of Assets | 0.01 | 0.01 | 0.04 |
| Loss (Gain) From Sale of Investments | -3.03 | -0.75 | - |
| Stock-Based Compensation | 6.41 | 5.66 | 6.1 |
| Provision & Write-off of Bad Debts | 0.09 | 0.05 | - |
| Other Operating Activities | 18.85 | 9.9 | -0.91 |
| Change in Accounts Receivable | -5.54 | -4.49 | - |
| Change in Inventory | -10.78 | -1.19 | - |
| Change in Accounts Payable | 2.26 | 0.72 | -0.08 |
| Change in Unearned Revenue | 1.91 | 0.34 | -0.18 |
| Change in Other Net Operating Assets | 2.68 | -0.68 | -2.53 |
| Operating Cash Flow | -40.34 | -32.45 | -60.21 |
| Capital Expenditures | -3.15 | -0.4 | -0.77 |
| Sale of Property, Plant & Equipment | 0.05 | 0 | 0 |
| Investment in Securities | -40.33 | -69.3 | - |
| Investing Cash Flow | -43.42 | -69.69 | -0.77 |
| Issuance of Common Stock | 0.07 | 0.03 | 0.39 |
| Other Financing Activities | 20.98 | 22.32 | 11.41 |
| Financing Cash Flow | -1.27 | 101.03 | 56.78 |
| Net Cash Flow | -85.03 | -1.11 | -4.2 |
| Free Cash Flow | -43.49 | -32.85 | -60.98 |
| Free Cash Flow Margin | -82.00% | -273.84% | -34067.04% |
| Free Cash Flow Per Share | -3.83 | -3.14 | -6.19 |
| Levered Free Cash Flow | - | -19.7 | - |
| Unlevered Free Cash Flow | - | -19.66 | - |
| Change in Net Working Capital | - | 4.6 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.